An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Table 1 Baseline characteristics of enrolled patients

Patient no.	Gender / age	Family history of diabetes	Underlying disease	BMI	Maximum dose of PSL	CRP	eGFR	HbA1c	Triglyceride	LDL / HDL ratio
Patient no.	Gender / age	Family history of diabetes	Underlying disease	kg/m²	mg/day	mg/dL	mL/min/ 1.73m²	%	mg/dL	LDL / HDL ratio
1	F / 82	Absent	Giant cell arteritis with polymyalgia rheumatica	16.3	30	4.2	47.1	5.8	94	2.2
2	F / 70	Present	Polymyalgia rheumatica	20.3	20	11.9	86.6	5.7	111	2.0
3	M / 72	Absent	Granulomatosis with polyangiitis	19.1	50	10.3	80.2	6.2	100	2.6
4	F / 77	Absent	Microscopic polyangiitis	20.5	35	11.3	16.3	5.9	118	1.1
5	M / 70	Absent	Membranoproliferative glomerulonephritis with cryoglobulinemia	18.4	30	0.16	100.2	4.6	82	0.2

BMI body mass index, CRP C-reactive protein, eGFR estimated glomerular filtration rate, F female, HbA1c hemoglobin A1c, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, M male, PSL prednisolone

ISSN: 1752-1947